浙江医药
(600216)
| 流通市值：138.57亿 | | | 总市值：138.57亿 |
| 流通股本：9.62亿 | | | 总股本：9.62亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,255,389,182.25 | 9,375,216,922.05 | 7,112,804,346.3 | 4,405,467,286.37 |
| 营业收入 | 2,255,389,182.25 | 9,375,216,922.05 | 7,112,804,346.3 | 4,405,467,286.37 |
| 二、营业总成本 | 1,778,067,510.03 | 7,934,024,498.03 | 6,103,341,032.99 | 4,013,409,994.55 |
| 营业成本 | 1,276,624,488.31 | 5,406,540,720.17 | 4,263,783,893.03 | 2,846,185,174.17 |
| 税金及附加 | 22,867,656.49 | 96,537,176.84 | 67,949,429 | 39,153,409.49 |
| 销售费用 | 240,680,661.64 | 1,100,198,245.79 | 849,542,121.05 | 537,172,530.81 |
| 管理费用 | 101,147,264.96 | 586,352,955.75 | 378,004,987.39 | 221,357,666.04 |
| 研发费用 | 177,463,871 | 749,353,351.93 | 546,930,073.32 | 377,483,069.83 |
| 财务费用 | -40,716,432.37 | -4,957,952.45 | -2,869,470.8 | -7,941,855.79 |
| 其中:利息费用 | 5,759,353.46 | 26,401,130.05 | 21,452,543.87 | 14,987,999.93 |
| 其中:利息收入 | 8,042,734.74 | 22,506,017.29 | 15,437,521.94 | 9,470,893.59 |
| 加:公允价值变动收益 | -2,145,344.99 | -21,534,114.35 | -3,578,166.01 | -11,590,057.79 |
| 加:投资收益 | 8,080,460.07 | -8,069,379.83 | -16,218,180.83 | -11,609,733.51 |
| 资产处置收益 | -899,293.52 | 3,090,739.73 | -818,044.51 | -958,361.51 |
| 资产减值损失(新) | -40,520,287.07 | -263,898,853.78 | -101,489,942.48 | -67,109,016.06 |
| 信用减值损失(新) | 1,014,082.9 | 343,806.26 | 191,890.43 | 275,244.2 |
| 其他收益 | 11,399,069.04 | 71,985,823.25 | 49,525,376.3 | 40,367,983.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 454,250,358.65 | 1,223,110,445.3 | 937,076,246.21 | 341,433,350.41 |
| 加:营业外收入 | 339,558.6 | 3,293,512.09 | 2,838,193.62 | 492,760.28 |
| 减:营业外支出 | 807,455.8 | 14,121,769.98 | 9,109,174.45 | 7,336,808.26 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 453,782,461.45 | 1,212,282,187.41 | 930,805,265.38 | 334,589,302.43 |
| 减:所得税费用 | 68,530,046.15 | 192,030,677.23 | 172,247,182.7 | 79,223,834.42 |
| 六、净利润 | 385,252,415.3 | 1,020,251,510.18 | 758,558,082.68 | 255,365,468.01 |
| 持续经营净利润 | 385,252,415.3 | 1,020,251,510.18 | 758,558,082.68 | 255,365,468.01 |
| 归属于母公司股东的净利润 | 409,085,292.06 | 1,160,510,670.41 | 849,651,818.01 | 315,332,017.87 |
| 少数股东损益 | -23,832,876.76 | -140,259,160.23 | -91,093,735.33 | -59,966,549.86 |
| (一)基本每股收益 | 0.43 | 1.21 | 0.88 | 0.33 |
| (二)稀释每股收益 | 0.43 | 1.21 | 0.88 | 0.33 |
| 八、其他综合收益 | 9,122,458.68 | -7,635,393.08 | -1,441,540.27 | -4,263,504.68 |
| 归属于母公司股东的其他综合收益 | 8,566,985.02 | -7,129,981.59 | -1,385,792.03 | -3,988,084.3 |
| 九、综合收益总额 | 394,374,873.98 | 1,012,616,117.1 | 757,116,542.41 | 251,101,963.33 |
| 归属于母公司股东的综合收益总额 | 417,652,277.08 | 1,153,380,688.82 | 848,266,025.98 | 311,343,933.57 |
| 归属于少数股东的综合收益总额 | -23,277,403.1 | -140,764,571.72 | -91,149,483.57 | -60,241,970.24 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-25 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |